{"id":14864,"date":"2021-08-03T00:00:00","date_gmt":"2021-08-03T00:00:00","guid":{"rendered":"https:\/\/cms.alj3.clients.lemonhq.io\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/"},"modified":"2026-05-13T06:17:54","modified_gmt":"2026-05-13T06:17:54","slug":"impulsar-el-progreso-a-traves-de-las-asociaciones","status":"publish","type":"perspectives","link":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/","title":{"rendered":"Impulsar el progreso a trav\u00e9s de las asociaciones"},"content":{"rendered":"

A Q&A with Prof. James J. Collins, newly appointed special advisor to Abdul Latif Jameel Health<\/h4>\n

As part of its mission to improve accessibility to high quality healthcare around the world, Abdul Latif Jameel Health<\/a> is continually looking to forge partnerships with the leading organizations, researchers innovators and thinkers in the global biotech and health industries.<\/p>\n

In May 2021, it appointed Professor James J. Collins as a special advisor. \u00a0James is the Termeer Professor of Medical Engineering & Science<\/a> in the Institute for Medical Engineering & Science (IMES<\/a>) and Department of Biological Engineering at the Massachusetts Institute of Technology (MIT<\/a>).<\/p>\n

His innovative research group works in synthetic and systems biology, developing novel and pioneering ways to \u2018reprogram\u2019 organisms, including bacteria, to perform targeted tasks, such as detecting and treating infections. \u00a0This may lead to cheaper drugs, rapid diagnostic tests, and more effective treatments for antibiotic-resistant infections and a range of complex diseases.<\/p>\n

\"Meet

James Collins and Regina Barzilay (center) were named as inaugural faculty co-leads of the Abdul Latif Jameel Clinic for Machine Learning in Health, (Jameel Clinic), by Anantha Chandrakasan (right), Dean of MIT School of Engineering and Jameel Clinic Chair with Prof. Philip Sharp (left) Chair of the Clinic\u2019s advisory Board \u2013 October 2018.<\/p><\/div>\n

Along with MIT colleague Regina Barzilay, James is a faculty co-lead<\/a> of the Abdul Latif Jameel Clinic for Machine Learning in Health, (Jameel Clinic<\/a>) at MIT<\/a> since its founding in 2018.<\/p>\n

We spoke to Professor Collins about his research, his new role at Abdul Latif Jameel Health, and his vision for the future of global healthcare.<\/p>\n

Could you provide a brief overview of your current work?<\/h2>\n

I am the Termeer Professor of Medical Engineering and Science in the Institute for Medical Engineering and Science as well as the Department of Biological Engineering.\u00a0 I am also co-faculty lead of the Jameel Clinic, which was established with a generous gift from Mohammed Jameel<\/a> and his family to serve as a nexus point for efforts at MIT focused on applying AI to the challenges of healthcare.<\/p>\n

In addition to my position at MIT, I am also a founding core faculty member of the Wyss Institute at Harvard<\/a> and an Institute Member at the Broad Institute<\/a> of MIT and Harvard.\u00a0 My lab primarily focuses on two areas:\u00a0 synthetic biology and antibiotics research, two areas that are increasingly tapping into the potential of AI to advance our knowledge and capabilities.<\/p>\n

When did you first become aware of Abdul Latif Jameel Health?<\/h2>\n

I quickly became connected with Mohammed Jameel and the Jameel Family<\/a>, together with Community Jameel<\/a>, and their broader interests in translational healthcare research. \u00a0It was probably within a year of my involvement with the Jameel Clinic that I became aware of Abdul Latif Jameel Health<\/a> more specifically. \u00a0Its mission resonates closely with my own approach.\u00a0 I was delighted to be asked to join as an advisor.\u00a0 My role is primarily to help Abdul Latif Jameel Health evaluate exciting opportunities for either investment or partnerships, such as the recent link-ups with Evelo Biosciences<\/a> and Cellarity.<\/p>\n

What do you see as the biggest challenges facing global healthcare currently?<\/h2>\n

\"ProfMost people think of global health challenges as being exclusively around infectious diseases. \u00a0In my own field, we work in infectious diseases, particularly antibiotics and increasingly now antivirals as a result of the COVID-19 pandemic.\u00a0 But an under-appreciated aspect is that developing countries are also saddled with major challenges around non-infectious diseases, including cancer and nerve degenerative conditions.<\/p>\n

So, the bigger challenge is how to make the marvelous advances that we are seeing in both infectious and non-infectious diseases affordable and accessible to everybody.<\/p>\n

Traditionally, most of the effort around global public health has been in the non-profit sphere. \u00a0One of the missions of Abdul Latif Jameel Health is to see how it can be achieved from a for-profit<\/em> perspective, leveraging the ability of market forces and market encouragement to drive meaningful change.<\/p>\n

At a personal level, many of my interests are in infectious disease, but we are increasingly looking to see how various tools from AI and synthetic biology can address other more complex diseases and may lend themselves well to addressing broader health challenges around the globe.<\/p>\n

Could you provide some examples of how technologies like AI, big data and machine learning are advancing innovation on healthcare?<\/h2>\n
\"Halicin\"

The now famous MIT image showing Halicin (top) preventing antibiotic resistance in E. coli, ciprofloxacin (bottom) did not.<\/p>\n

Photo Credit \u00a9 courtesy Collins Lab at MIT<\/p><\/div>\n

If we take antibiotics first, as part of the Jameel Clinic, Regina Barzilay, Tommi Jaakkola and myself collaborated to see if we could harness the power of AI to address the antibiotic resistance crisis.\u00a0 We were able to advance a pilot effort where we trained an AI model to help us identify a potent new antibiotic called Halicin<\/a> that was very effective against a broad range of pathogens, including multi-drug resistant, extensively drug-resistant and pan-resistant pathogens.<\/p>\n

We were subsequently able to apply the model to an enormous library of 1.5 billion molecules in just a few days, identifying a large number of other new antibiotic candidates.<\/p>\n

We have now launched the Antibiotics-AI project at MIT through the Jameel Clinic, with the goal of using AI to design and discover a novel class of antibiotics, as we did with Halicin.<\/p>\n

On the synthetic biology side, we have previously established that you can use engineered synthetic gene circuits along with cell-free extracts.\u00a0 In the case of cell-free systems, you can open up a living cell and take the \u2018machinery\u2019 out of that cell.\u00a0 Our advance was to show you could freeze-dry these cell-free extract along with synthetic biology gene circuits onto paper in order to create inexpensive paper based diagnostics.<\/p>\n

Perhaps most stunningly, in the midst of the COVID-19 pandemic and under the auspices of the Jameel Clinic, in part, we showed we could use synthetic biology to create a COVID-19 facemask diagnostic that could give an output in a relatively few minutes with high sensitivity and high specificity to SARS-CoV-2.\u00a0 In short, a facemask which could tell you if you had COVID-19.<\/p>\n

How close to commercialization are these advances?<\/h2>\n

With Halicin, we are now advancing it further towards a potential clinical trial; exploring its toxicity, developing analogues to address the toxicity, and scoping out additional aspects of its drug-like properties.<\/p>\n

With regard to the paper-based diagnostic, we have a spinout from MIT, Sherlock Biosciences<\/a>, which has developed an FDA-approved COVID-19 diagnostic based on our synthetic biology platform<\/a>.\u00a0 This has now been adopted by multiple global diagnostic firms, as well as the country of Nepal as their national test. Sherlock Biosciences and its partners are now on pace to use our technology to conduct 10M COVID-19 diagnostic tests each month in countries around the globe.<\/p>\n

The diagnostic facemask is still at the academic stage.\u00a0 It is not yet commercialized, but it is an interesting opportunity to explore as to how could we move this from a lab demo at MIT and the Wyss Institute to a product that might be available at your local pharmacy.<\/p>\n

How important is it to make sure that innovations like these get out into the whole world and don\u2019t only become healthcare for wealthy nations?<\/h2>\n

It is an important part of my mission as a professor and an entrepreneur to try and ensure that our technologies are available to all.\u00a0 We too often see companies that are driven for profit over impact, particularly in the US.\u00a0 For me, impact is much more important than profit.\u00a0 I would much rather see a product that benefits millions of individuals than make millions of dollars off the product.<\/p>\n

Has the COVID-19 pandemic encouraged people to think more about this aspect?<\/h2>\n

It has, but not as much as it should.\u00a0 Greed is unfortunately a very powerful force in this world.<\/p>\n

\"221BThis is why, through Sherlock Biosciences, we have established a foundation called The 221b Foundation<\/a>, named after Sherlock Holmes\u2019 fictional address in London.<\/p>\n

We have committed to donating all profits from our COVID-19 product to the foundation, as well as making all our IP around CRISPR diagnostics available to any organization that would like to develop COVID-19 diagnostics, on the understanding that the profits need to come back to the foundation.<\/p>\n

These profits are then dedicated to advancing STEM (Science, Technology, Engineering and Mathematics) efforts for under-represented minorities, trying to encourage more young people to study STEM subjects, to advance technologies and to address global health challenges.<\/p>\n

How is the Jameel Clinic as a whole helping to address some of these issues?<\/h2>\n
\"Jameel

Hassan Jameel (L), L. Rafael Reif, President MIT (C) and Fady Jameel (R) at the foundation ceremony of the Jameel Clinic at MIT, 2018.<\/p><\/div>\n

The Jameel Clinic was formed approximately three years ago [2018], and it has been thriving since then, with a number of exciting programs underway.<\/p>\n

In the midst of the pandemic, the Clinic launched a program called AI Cures, which aims to advance AI to address emerging pathogens, including SARS-CoV-2.\u00a0 As part of this initiative, we were able to pull together a number of interesting datasets that were made accessible to researchers around the world.<\/p>\n

Working with Regina Barzilay and Tommi Jaakkola and a number of their graduate students, we were also able to use AI, for example, to develop effective combinations for treating SARS-CoV-2, the pathogen that causes COVID-19.<\/p>\n

What is it about AI, big data and machine learning that makes them such gamechangers in healthcare innovation?<\/h2>\n

The key aspect to AI and big data is that these resources enable us to embrace the complexity of biology and chemistry at a scale well beyond anything our brains alone could achieve.<\/p>\n

\"JamesEven the simplest of living cells, bacteria, are much more complicated than the most complicated machine we have ever designed on Earth.\u00a0 It is effectively impossible to comprehensively understand how such a living system evolved over the course of billions of years.<\/p>\n

Similarly, it is incredibly difficult to understand how a drug that we are developing could affect the complex biology of a living cell or set of cells.\u00a0 Big data and AI enable us to do that.\u00a0 We can use these technologies to query the biology of a living cell at a scale that we previously could not.\u00a0 It enables us to understand the interaction between molecules to generate better insights into how all these amazing components in a living cell interact to create a healthy state and how they might break down in their interactions to create a disease state.\u00a0 This allows us to identify how we could potentially intervene to correct or improve upon a diseased or injured state.<\/p>\n

Is the potential of these technologies yet fully understood?<\/h2>\n

Not at all, we are still very early days in applying AI to challenges in health care.\u00a0 We have seen AI and big data have a huge impact in the information world and the internet, but in the fields of biology and medicine, the age of big data is still in its infancy.\u00a0 I think we will see increasing advancements in the next decade or two as more and more data are collected and made available.\u00a0 One of our missions at the Jameel Clinic is to train the next generation of healthcare researchers to be multi-disciplinary, so they have expertise in both AI\/machine learning and in biology and chemistry, allowing them to work at the interface of technology, science and medicine to make breakthroughs that matter for patients.<\/p>\n

Looking ahead, what do you think the medium-to-longer-term future of global health care looks like?<\/h2>\n

I think one of the few advantages of the pandemic is a growing awareness among young people of the importance of infectious disease as a serious issue worthy of their attention. \u00a0So, I think we will see more young talent coming into the field of infectious diseases and global health, which will certainly advance our knowledge and our abilities to detect, treat and prevent infections.<\/p>\n

Looking ahead, we will certainly see dramatic, impressive changes and advances in biomedicine.\u00a0 We will see the growing impact of big data, advanced technologies including AI and synthetic biology, to advance efforts that enable us to better diagnose disease, treat disease, and prevent disease across the globe, in a way that is economically efficient and hopefully affordable to all.<\/p>\n","protected":false},"featured_media":14852,"menu_order":0,"template":"","class_list":["post-14864","perspectives","type-perspectives","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\nImpulsar el progreso a trav\u00e9s de las asociaciones - Abdul Latif Jameel<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Impulsar el progreso a trav\u00e9s de las asociaciones - Abdul Latif Jameel\" \/>\n<meta property=\"og:description\" content=\"A Q&A with Prof. James J. Collins, newly appointed special advisor to Abdul Latif Jameel Health As part of its mission to improve accessibility to high quality healthcare around the world, Abdul Latif Jameel Health is continually looking to forge partnerships with the leading organizations, researchers innovators and thinkers in the global biotech and health […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/\" \/>\n<meta property=\"og:site_name\" content=\"Abdul Latif Jameel\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-13T06:17:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Prof-James-J.-Collins.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2067\" \/>\n\t<meta property=\"og:image:height\" content=\"1176\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/\",\"url\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/\",\"name\":\"Impulsar el progreso a trav\u00e9s de las asociaciones - Abdul Latif Jameel\",\"isPartOf\":{\"@id\":\"https:\/\/10.0.2.222\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Prof-James-J.-Collins.jpg\",\"datePublished\":\"2021-08-03T00:00:00+00:00\",\"dateModified\":\"2026-05-13T06:17:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/#primaryimage\",\"url\":\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Prof-James-J.-Collins.jpg\",\"contentUrl\":\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Prof-James-J.-Collins.jpg\",\"width\":2067,\"height\":1176},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/10.0.2.222\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Impulsar el progreso a trav\u00e9s de las asociaciones\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/10.0.2.222\/en\/#website\",\"url\":\"https:\/\/10.0.2.222\/en\/\",\"name\":\"Abdul Latif Jameel\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/10.0.2.222\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Impulsar el progreso a trav\u00e9s de las asociaciones - Abdul Latif Jameel","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"es_ES","og_type":"article","og_title":"Impulsar el progreso a trav\u00e9s de las asociaciones - Abdul Latif Jameel","og_description":"A Q&A with Prof. James J. Collins, newly appointed special advisor to Abdul Latif Jameel Health As part of its mission to improve accessibility to high quality healthcare around the world, Abdul Latif Jameel Health is continually looking to forge partnerships with the leading organizations, researchers innovators and thinkers in the global biotech and health […]","og_url":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/","og_site_name":"Abdul Latif Jameel","article_modified_time":"2026-05-13T06:17:54+00:00","og_image":[{"width":2067,"height":1176,"url":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Prof-James-J.-Collins.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/","url":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/","name":"Impulsar el progreso a trav\u00e9s de las asociaciones - Abdul Latif Jameel","isPartOf":{"@id":"https:\/\/10.0.2.222\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/#primaryimage"},"image":{"@id":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/#primaryimage"},"thumbnailUrl":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Prof-James-J.-Collins.jpg","datePublished":"2021-08-03T00:00:00+00:00","dateModified":"2026-05-13T06:17:54+00:00","breadcrumb":{"@id":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/#primaryimage","url":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Prof-James-J.-Collins.jpg","contentUrl":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Prof-James-J.-Collins.jpg","width":2067,"height":1176},{"@type":"BreadcrumbList","@id":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/impulsar-el-progreso-a-traves-de-las-asociaciones\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/10.0.2.222\/en\/"},{"@type":"ListItem","position":2,"name":"Impulsar el progreso a trav\u00e9s de las asociaciones"}]},{"@type":"WebSite","@id":"https:\/\/10.0.2.222\/en\/#website","url":"https:\/\/10.0.2.222\/en\/","name":"Abdul Latif Jameel","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/10.0.2.222\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"}]}},"post-meta-fields":{"_wp_page_template":["default"],"_published_date":["field_6057129b493f5"],"published_date":["20210803"],"_location":["field_601267396ce72"],"location":["Dubai, EAU"],"_featured":["field_601a3b473c5c5"],"featured":["0"],"_footnotes":["field_66fd39afb9383"],"footnotes":[""],"_business_sector":["field_66f6b5bcac8cb"],"business_sector":["Salud"],"_content_series":["field_66fe3c439f8f6"],"content_series":[""],"_old_post_id":["field_66fe3fd59f8f7"],"old_post_id":["90882"],"_short_title":["field_60925d67125ef"],"short_title":["Impulsar el progreso a trav\u00e9s de las asociaciones"],"_summary":["field_6019304103a20"],"summary":["<p>Preguntas y respuestas con el profesor James J. Collins, recientemente nombrado asesor especial de Abdul Latif Jameel Health<\/p>"],"_mobile_featured_image":["field_66f6b4bee65f3"],"mobile_featured_image":["https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Prof-James-J.-Collins.jpg"],"_push_notification":["field_66f6b47de65f1"],"push_notification":[""],"_publish_mobile":["field_66f6b491e65f2"],"publish_mobile":["0"],"_status":["field_652694983fe12"],"status":["publish"],"_thumbnail_id":["14852"],"_wpml_word_count":["{\"total\":2284,\"to_translate\":{\"ar\":2284,\"zh-hans\":2284,\"fr\":2284,\"ja\":2284,\"es\":2284,\"tr\":2284}}"],"_last_translation_edit_mode":["native-editor"],"amazonS3_cache":["a:22:{s:80:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/J-Clinic-Leadership.jpg\";a:2:{s:2:\"id\";s:5:\"17117\";s:11:\"source_type\";s:13:\"media-library\";}s:88:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/J-Clinic-Leadership-300x182.jpg\";a:2:{s:2:\"id\";s:5:\"17117\";s:11:\"source_type\";s:13:\"media-library\";}s:82:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/J-Clinic-Leadership.jpg\";a:2:{s:2:\"id\";s:5:\"17117\";s:11:\"source_type\";s:13:\"media-library\";}s:90:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/J-Clinic-Leadership-300x182.jpg\";a:2:{s:2:\"id\";s:5:\"17117\";s:11:\"source_type\";s:13:\"media-library\";}s:92:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Prof-James-J.-Collins-test-tube.jpg\";a:2:{s:2:\"id\";s:5:\"17467\";s:11:\"source_type\";s:13:\"media-library\";}s:100:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Prof-James-J.-Collins-test-tube-192x300.jpg\";a:2:{s:2:\"id\";s:5:\"17467\";s:11:\"source_type\";s:13:\"media-library\";}s:94:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Prof-James-J.-Collins-test-tube.jpg\";a:2:{s:2:\"id\";s:5:\"17467\";s:11:\"source_type\";s:13:\"media-library\";}s:102:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Prof-James-J.-Collins-test-tube-192x300.jpg\";a:2:{s:2:\"id\";s:5:\"17467\";s:11:\"source_type\";s:13:\"media-library\";}s:80:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/halicin-antibiotics.jpg\";a:2:{s:2:\"id\";s:5:\"17410\";s:11:\"source_type\";s:13:\"media-library\";}s:88:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/halicin-antibiotics-300x300.jpg\";a:2:{s:2:\"id\";s:5:\"17410\";s:11:\"source_type\";s:13:\"media-library\";}s:82:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/halicin-antibiotics.jpg\";a:2:{s:2:\"id\";s:5:\"17410\";s:11:\"source_type\";s:13:\"media-library\";}s:90:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/halicin-antibiotics-300x300.jpg\";a:2:{s:2:\"id\";s:5:\"17410\";s:11:\"source_type\";s:13:\"media-library\";}s:67:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Logo-1.jpg\";a:2:{s:2:\"id\";s:5:\"17468\";s:11:\"source_type\";s:13:\"media-library\";}s:69:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Logo-1.jpg\";a:2:{s:2:\"id\";s:5:\"17468\";s:11:\"source_type\";s:13:\"media-library\";}s:82:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Hassan-Jameel-JClinic.jpg\";a:2:{s:2:\"id\";s:5:\"17121\";s:11:\"source_type\";s:13:\"media-library\";}s:90:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Hassan-Jameel-JClinic-300x200.jpg\";a:2:{s:2:\"id\";s:5:\"17121\";s:11:\"source_type\";s:13:\"media-library\";}s:84:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Hassan-Jameel-JClinic.jpg\";a:2:{s:2:\"id\";s:5:\"17121\";s:11:\"source_type\";s:13:\"media-library\";}s:92:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Hassan-Jameel-JClinic-300x200.jpg\";a:2:{s:2:\"id\";s:5:\"17121\";s:11:\"source_type\";s:13:\"media-library\";}s:78:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/James-J-Collins-T.jpg\";a:2:{s:2:\"id\";s:4:\"9557\";s:11:\"source_type\";s:13:\"media-library\";}s:86:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/James-J-Collins-T-300x162.jpg\";a:2:{s:2:\"id\";s:4:\"9557\";s:11:\"source_type\";s:13:\"media-library\";}s:80:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/James-J-Collins-T.jpg\";a:2:{s:2:\"id\";s:4:\"9557\";s:11:\"source_type\";s:13:\"media-library\";}s:88:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/James-J-Collins-T-300x162.jpg\";a:2:{s:2:\"id\";s:4:\"9557\";s:11:\"source_type\";s:13:\"media-library\";}}"],"_edit_lock":["1778655148:22"],"content":["<h4>Preguntas y respuestas con el profesor James J. Collins, recientemente nombrado asesor especial de Abdul Latif Jameel Health<\/h4>\r\n<p>Como parte de su misi\u00f3n de mejorar la accesibilidad a la atenci\u00f3n sanitaria de alta calidad en todo el mundo, <a href=\"https:\/\/aljhealth.com\">Abdul Latif Jameel Health<\/a> busca continuamente forjar asociaciones con las principales organizaciones, investigadores, innovadores y pensadores en las industrias mundiales de la biotecnolog\u00eda y la salud.<\/p>\r\n<p>En mayo de 2021, nombr\u00f3 al profesor James J. Collins como asesor especial. James es el <a href=\"https:\/\/be.mit.edu\/directory\/james-j-collins\">profesor Termeer de Ingenier\u00eda M\u00e9dica y Ciencia<\/a> en el Instituto de Ingenier\u00eda M\u00e9dica y Ciencia (<a href=\"https:\/\/imes.mit.edu\/\">IMES<\/a>) y el Departamento de Ingenier\u00eda Biol\u00f3gica del Instituto Tecnol\u00f3gico de Massachusetts (<a href=\"https:\/\/mit.edu\/\">ITM<\/a>).<\/p>\r\n<p>Su innovador grupo de investigaci\u00f3n trabaja en biolog\u00eda sint\u00e9tica y de sistemas, desarrollando formas novedosas y pioneras de \u201creprogramar\u201d organismos, incluidas las bacterias, para realizar tareas espec\u00edficas, como la detecci\u00f3n y el tratamiento de infecciones. Esto puede dar lugar a f\u00e1rmacos m\u00e1s baratos, pruebas diagn\u00f3sticas r\u00e1pidas y tratamientos m\u00e1s eficaces para infecciones resistentes a los antibi\u00f3ticos y una serie de enfermedades complejas.<\/p>\r\n\r\n[caption id=\"attachment_53490\" align=\"alignright\" width=\"300\"]<img class=\"size-medium wp-image-53490\" src=\"https:\/\/www.alj.com\/app\/uploads\/2019\/11\/J-Clinic-Leadership-300x182.jpg\" alt=\"Meet the J-Clinic leadership team (L-R): Phillip A. Sharp, Chair, Advisory Board; James J. Collins & Regina Barizlay, Faculty Leads; Anantha P. Chandrakasan, Chair, J-Clinic.\" width=\"300\" height=\"182\" \/> James Collins y Regina Barzilay (centro) fueron nombrados codirectores inaugurales del profesorado de la Cl\u00ednica Abdul Latif Jameel para el aprendizaje autom\u00e1tico en salud, (cl\u00ednica Jameel), por Anantha Chandrakasan (derecha), decano de la Escuela de Ingenier\u00eda del ITM y presidente de la Cl\u00ednica Jameel con el profesor Philip Sharp (izquierda) presidente de la junta asesora de la Cl\u00ednica \u2013 octubre de 2018.[\/caption]\r\n\r\n<p>Junto con su compa\u00f1era del ITM Regina Barzilay, James es <a href=\"https:\/\/news.mit.edu\/2018\/mit-barzilay-collins-sharp-lead-j-clinic-machine-learning-health-1003\">codirector de la facultad<\/a> de la Cl\u00ednica Abdul Latif Jameel para el Aprendizaje Autom\u00e1tico en Salud, (<a href=\"https:\/\/www.jclinic.mit.edu\/\">Cl\u00ednica Jameel<\/a>) en el <a href=\"https:\/\/mit.edu\">\u00a0ITM<\/a> desde su fundaci\u00f3n en 2018.<\/p>\r\n<p>Hablamos con el profesor Collins sobre su investigaci\u00f3n, su nuevo cargo en Abdul Latif Jameel Health y su visi\u00f3n del futuro de la sanidad mundial.<\/p>\r\n<h2>\u00bfPodr\u00eda hacer una breve descripci\u00f3n de su trabajo actual?<\/h2>\r\n<p>Soy profesor Termeer de Ingenier\u00eda y Ciencia M\u00e9dica en el Instituto de Ingenier\u00eda y Ciencia M\u00e9dica, as\u00ed como en el Departamento de Ingenier\u00eda Biol\u00f3gica. Tambi\u00e9n soy cofundador de la Cl\u00ednica Jameel, creada gracias a una generosa donaci\u00f3n de <a href=\"https:\/\/www.alj.com\/en\/our-people\/mohammed-abdul-latif-jameel\/\">Mohammed Jameel<\/a> y su familia, con el fin de servir de punto de enlace para los esfuerzos del ITM centrados en aplicar la IA a los desaf\u00edos de la atenci\u00f3n sanitaria.<\/p>\r\n<p>Adem\u00e1s de mi puesto en el ITM, tambi\u00e9n soy miembro fundador del cuerpo docente principal del <a href=\"https:\/\/wyss.harvard.edu\/\">Wyss Institute en Harvard<\/a> y miembro del instituto en el <a href=\"https:\/\/www.broadinstitute.org\/\">Broad Institute<\/a> del ITM y Harvard. Mi laboratorio se centra principalmente en dos \u00e1reas: la biolog\u00eda sint\u00e9tica y la investigaci\u00f3n de antibi\u00f3ticos, dos \u00e1reas que est\u00e1n aprovechando cada vez m\u00e1s el potencial de la IA para hacer avanzar nuestros conocimientos y capacidades.<\/p>\r\n<h2>\u00bfCu\u00e1ndo conoci\u00f3 Abdul Latif Jameel Health?<\/h2>\r\n<p>R\u00e1pidamente me puse en contacto con Mohammed Jameel y la <a href=\"https:\/\/www.communityjameel.org\/en\/who-we-are\/jameel-family\">Familia Jameel<\/a>, junto con <a href=\"https:\/\/www.communityjameel.org\">Community Jameel<\/a>, y sus intereses m\u00e1s amplios en la investigaci\u00f3n traslacional de la atenci\u00f3n sanitaria. Fue probablemente al a\u00f1o de mi participaci\u00f3n en la Cl\u00ednica Jameel cuando conoc\u00ed <a href=\"https:\/\/aljhealth.com\">Abdul Latif Jameel Health<\/a> m\u00e1s espec\u00edficamente. Su misi\u00f3n coincide con mi propio enfoque. Me encant\u00f3 que me pidieran que me uniera como asesor; consiste principalmente en ayudar a Abdul Latif Jameel Health a evaluar oportunidades interesantes de inversi\u00f3n o asociaci\u00f3n, como las recientes alianzas con <a href=\"https:\/\/www.alj.com\/en\/perspective\/a-stomach-for-innovation-a-qa-with-ceos-of-evelo-biosciences-and-abdul-latif-jameel-health-on-their-exciting-new-adventure\/\">Evelo Biosciences<\/a> y Cellarity.<\/p>\r\n<h2>\u00bfCu\u00e1les son, en su opini\u00f3n, los mayores retos a los que se enfrenta actualmente la sanidad mundial?<\/h2>\r\n<p><img class=\"alignleft size-medium wp-image-90856\" src=\"https:\/\/www.alj.com\/app\/uploads\/2021\/08\/Prof-James-J.-Collins-test-tube-192x300.jpg\" alt=\"Prof James J. Collins\" width=\"192\" height=\"300\" \/>La mayor\u00eda de la gente piensa que los retos de la salud mundial giran exclusivamente en torno a las enfermedades infecciosas. En mi campo, trabajamos en el \u00e1mbito de las enfermedades infecciosas, sobre todo en el de los antibi\u00f3ticos y, cada vez m\u00e1s, en el de los antivirales, como resultado de la pandemia de COVID-19. Pero un aspecto que no se tiene en cuenta es que los pa\u00edses en v\u00edas de desarrollo tambi\u00e9n se enfrentan a grandes desaf\u00edos en torno a las enfermedades no infecciosas, como el c\u00e1ncer y las enfermedades degenerativas nerviosas.<\/p>\r\n<p>Por lo tanto, el mayor desaf\u00edo es c\u00f3mo hacer que los maravillosos avances que estamos viendo tanto en enfermedades infecciosas como no infecciosas sean asequibles y accesibles para todos.<\/p>\r\n<p>Tradicionalmente, la mayor parte de los esfuerzos en torno a la salud p\u00fablica mundial se han realizado en el \u00e1mbito de las organizaciones sin \u00e1nimo de lucro. Una de las misiones de Abdul Latif Jameel Health es ver c\u00f3mo se puede lograr desde una perspectiva <em>con \u00e1nimo de lucro<\/em> aprovechando la capacidad de las fuerzas del mercado y el est\u00edmulo de este para impulsar un cambio significativo.<\/p>\r\n<p>A nivel personal, muchos de mis intereses se centran en las enfermedades infecciosas, pero cada vez m\u00e1s buscamos c\u00f3mo diversas herramientas de la IA y la biolog\u00eda sint\u00e9tica pueden hacer frente a otras enfermedades m\u00e1s complejas y pueden prestarse bien a abordar retos sanitarios m\u00e1s amplios en todo el mundo.<\/p>\r\n<h2>\u00bfPodr\u00eda dar algunos ejemplos de c\u00f3mo las tecnolog\u00edas como la IA, los macrodatos y el aprendizaje autom\u00e1tico est\u00e1n haciendo avanzar la innovaci\u00f3n en la atenci\u00f3n sanitaria?<\/h2>\r\n\r\n[caption id=\"attachment_57746\" align=\"alignright\" width=\"300\"]<img class=\"size-medium wp-image-57746\" src=\"https:\/\/www.alj.com\/app\/uploads\/2020\/02\/halicin-antibiotics-300x300.jpg\" alt=\"Halicin\" width=\"300\" height=\"300\" \/> La ahora famosa imagen del ITM que muestra que la halicina (arriba) previene la resistencia a los antibi\u00f3ticos en E. coli, mientras que la ciprofloxacina (abajo) no.<br \/>\r\nCr\u00e9dito de la foto \u00a9 cortes\u00eda de Collins Lab del ITM[\/caption]\r\n\r\n<p>Si hablamos de los antibi\u00f3ticos en primer lugar, como parte de la Cl\u00ednica Jameel, Regina Barzilay, Tommi Jaakkola y yo mismo colaboramos para ver si pod\u00edamos aprovechar el poder de la IA para abordar la crisis de la resistencia a los antibi\u00f3ticos. Fuimos capaces de avanzar en un esfuerzo piloto en el que entrenamos un modelo de IA para ayudarnos a identificar un nuevo y potente antibi\u00f3tico llamado <a href=\"https:\/\/www.alj.com\/en\/news\/j-clinic-discovers-powerful-new-antibiotic-using-ai-technology\/\">halicina<\/a>, que era muy eficaz contra una amplia gama de pat\u00f3genos, incluidos los multirresistentes, los ampliamente resistentes a los f\u00e1rmacos y los panresistentes.<\/p>\r\n<p>Posteriormente pudimos aplicar el modelo a una enorme biblioteca de 1500 millones de mol\u00e9culas en solo unos d\u00edas, identificando un gran n\u00famero de otros nuevos candidatos a antibi\u00f3ticos.<\/p>\r\n<p>Ya hemos lanzado el proyecto Antibiotics-AI en el ITM a trav\u00e9s de la Cl\u00ednica Jameel, con el objetivo de utilizar la IA para dise\u00f1ar y descubrir una nueva clase de antibi\u00f3ticos, como hicimos con la halicina.<\/p>\r\n<p>En cuanto a la biolog\u00eda sint\u00e9tica, ya hemos establecido que se pueden utilizar circuitos gen\u00e9ticos sint\u00e9ticos dise\u00f1ados junto con extractos libres de c\u00e9lulas. En el caso de los sistemas sin c\u00e9lulas, puede abrir una c\u00e9lula viva y sacar la \u201cmaquinaria\u201d de esa c\u00e9lula. Nuestro avance fue demostrar que pod\u00edamos liofilizar estos extractos libres de c\u00e9lulas junto con circuitos gen\u00e9ticos de biolog\u00eda sint\u00e9tica en papel para crear diagn\u00f3sticos baratos basados en papel.<\/p>\r\n<p>Quiz\u00e1s lo m\u00e1s sorprendente es que, en medio de la pandemia de COVID-19 y bajo los auspicios de la Cl\u00ednica Jameel, en parte, demostramos que pod\u00edamos usar la biolog\u00eda sint\u00e9tica para crear un diagn\u00f3stico de COVID-19 con mascarilla que pod\u00eda dar un resultado en relativamente pocos minutos con alta sensibilidad y especificidad al SARS-CoV-2. En resumen, una mascarilla que podr\u00eda indicarte si tienes COVID-19.<\/p>\r\n<h2>\u00bfHasta qu\u00e9 punto est\u00e1n cerca de la comercializaci\u00f3n estos avances?<\/h2>\r\n<p>En el caso de la halicina, estamos avanzando hacia un posible ensayo cl\u00ednico, explorando su toxicidad, desarrollando an\u00e1logos para abordar la toxicidad y estudiando otros aspectos de sus propiedades farmacol\u00f3gicas.<\/p>\r\n<p>En cuanto al diagn\u00f3stico en papel, tenemos una derivaci\u00f3n del ITM, <a href=\"https:\/\/sherlock.bio\/\">Sherlock Biosciences<\/a>, que ha desarrollado un <a href=\"https:\/\/sherlock.bio\/sherlock-biosciences-receives-fda-emergency-use-authorization-for-crispr-sars-cov-2-rapid-diagnostic\/\">diagn\u00f3stico de COVID-19 aprobado por la FDA y basado en nuestra plataforma de biolog\u00eda sint\u00e9tica<\/a>. Ahora ha sido adoptado por m\u00faltiples empresas de diagn\u00f3stico mundiales, as\u00ed como por el pa\u00eds de Nepal como su prueba nacional. Sherlock Biosciences y sus socios est\u00e1n ahora a punto de utilizar nuestra tecnolog\u00eda para realizar 10 millones de pruebas de diagn\u00f3stico de COVID-19 cada mes en pa\u00edses de todo el mundo.<\/p>\r\n<p>La mascarilla de diagn\u00f3stico a\u00fan est\u00e1 en fase acad\u00e9mica. A\u00fan no se ha comercializado, pero es una oportunidad interesante para explorar c\u00f3mo podr\u00edamos pasar de una demostraci\u00f3n de laboratorio en el ITM y el Wyss Institute a un producto que podr\u00eda estar disponible en su farmacia local.<\/p>\r\n<h2>\u00bfHasta qu\u00e9 punto es importante asegurarse de que innovaciones como estas lleguen a todo el mundo y no solo se conviertan en atenci\u00f3n sanitaria para las naciones ricas?<\/h2>\r\n<p>Una parte importante de mi misi\u00f3n como profesor y empresario es intentar que nuestras tecnolog\u00edas est\u00e9n al alcance de todos. Con demasiada frecuencia vemos empresas que se gu\u00edan por los beneficios en lugar de por el impacto, especialmente en Estados Unidos. Para m\u00ed, el impacto es mucho m\u00e1s importante que los beneficios. Preferir\u00eda ver un producto que beneficie a millones de personas en vez de ganar millones de d\u00f3lares con el producto.<\/p>\r\n<h2>\u00bfLa pandemia de COVID-19 ha animado a la gente a pensar m\u00e1s en este aspecto?<\/h2>\r\n<p>Lo ha hecho, pero no tanto como deber\u00eda. La codicia es, por desgracia, una fuerza muy poderosa en este mundo.<\/p>\r\n<p><img class=\"alignright size-full wp-image-90849\" src=\"https:\/\/www.alj.com\/app\/uploads\/2021\/08\/Logo.jpg\" alt=\"221B Foundation Logo\" width=\"195\" height=\"88\" \/>Por este motivo, a trav\u00e9s de Sherlock Biosciences, hemos creado una fundaci\u00f3n llamada <u>The <\/u><a href=\"https:\/\/221bfoundation.org\/\">221b Foundation<\/a>, nombrada as\u00ed por la direcci\u00f3n ficticia de Sherlock Holmes en Londres.<\/p>\r\n<p>Nos hemos comprometido a donar todos los beneficios de nuestro producto COVID-19 a la fundaci\u00f3n, as\u00ed como a poner toda nuestra propiedad intelectual en torno al diagn\u00f3stico CRISPR a disposici\u00f3n de cualquier organizaci\u00f3n que quiera desarrollar diagn\u00f3sticos de COVID-19, entendiendo que los beneficios deben volver a la fundaci\u00f3n.<\/p>\r\n<p>Estos beneficios se dedican a impulsar los esfuerzos de STEM (Ciencia, Tecnolog\u00eda, Ingenier\u00eda y Matem\u00e1ticas) para las minor\u00edas infrarrepresentadas, tratando de animar a m\u00e1s j\u00f3venes a estudiar materias STEM, a avanzar en las tecnolog\u00edas y a abordar los retos sanitarios mundiales.<\/p>\r\n<h2>\u00bfC\u00f3mo ayuda la Cl\u00ednica Jameel en su conjunto a resolver algunos de estos problemas?<\/h2>\r\n\r\n[caption id=\"attachment_53568\" align=\"alignright\" width=\"300\"]<img class=\"size-medium wp-image-53568\" src=\"https:\/\/www.alj.com\/app\/uploads\/2019\/11\/Hassan-Jameel-JClinic-300x200.jpg\" alt=\"Jameel Clinic\" width=\"300\" height=\"200\" \/> Hassan Jameel (L), L. Rafael Reif, presidente del ITM (C) y Fady Jameel (R) en la ceremonia de fundaci\u00f3n de la Cl\u00ednica Jameel en el ITM, 2018.[\/caption]\r\n\r\n<p>La Cl\u00ednica Jameel se form\u00f3 hace aproximadamente tres a\u00f1os [2018] y ha estado prosperando desde entonces, con una serie de emocionantes programas en marcha.<\/p>\r\n<p>En medio de la pandemia, la Cl\u00ednica lanz\u00f3 un programa llamado IA Cures, que tiene como objetivo hacer avanzar la IA para hacer frente a los pat\u00f3genos emergentes, incluido el SARS-CoV-2. Como parte de esta iniciativa, pudimos reunir una serie de conjuntos de datos interesantes que fueron puestos a disposici\u00f3n de investigadores de todo el mundo.<\/p>\r\n<p>Al trabajar con Regina Barzilay y Tommi Jaakkola y varios de sus estudiantes de posgrado, tambi\u00e9n pudimos utilizar la IA, por ejemplo, para desarrollar combinaciones eficaces para tratar el SARS-CoV-2, el pat\u00f3geno que causa la COVID-19.<\/p>\r\n<h2>\u00bfQu\u00e9 tienen la IA, los macrodatos y el aprendizaje autom\u00e1tico que los convierte en elementos tan revolucionarios en la innovaci\u00f3n sanitaria?<\/h2>\r\n<p>El aspecto clave de la IA y los macrodatos es que estos recursos nos permiten abarcar la complejidad de la biolog\u00eda y la qu\u00edmica a una escala muy superior a la que podr\u00edan alcanzar nuestros cerebros por s\u00ed solos.<\/p>\r\n<p><img class=\"alignleft wp-image-87908 size-medium\" src=\"https:\/\/www.alj.com\/app\/uploads\/2021\/04\/James-J-Collins-T-300x162.jpg\" alt=\"James J Collins\" width=\"300\" height=\"162\" \/><\/p>\r\n<p>Incluso las c\u00e9lulas vivas m\u00e1s simples, las bacterias, son mucho m\u00e1s complicadas que la m\u00e1quina m\u00e1s complicada que hayamos dise\u00f1ado en la Tierra. Es realmente imposible entender de forma exhaustiva c\u00f3mo ha evolucionado un sistema vivo de estas caracter\u00edsticas a lo largo de miles de millones de a\u00f1os.<\/p>\r\n<p>Del mismo modo, es incre\u00edblemente dif\u00edcil entender c\u00f3mo un f\u00e1rmaco que estamos desarrollando podr\u00eda afectar a la compleja biolog\u00eda de una c\u00e9lula o conjunto de c\u00e9lulas vivas. Los macrodatos y la IA nos permiten hacerlo. Podemos utilizar estas tecnolog\u00edas para consultar la biolog\u00eda de una c\u00e9lula viva a una escala que antes no pod\u00edamos utilizar. Nos permite comprender la interacci\u00f3n entre mol\u00e9culas para generar una mejor comprensi\u00f3n sobre c\u00f3mo todos estos incre\u00edbles componentes de una c\u00e9lula viva interact\u00faan para crear un estado saludable y c\u00f3mo pueden descomponerse en sus interacciones para crear un estado de enfermedad. Esto nos permite identificar c\u00f3mo podr\u00edamos intervenir para corregir o mejorar un estado de enfermedad o lesi\u00f3n.<\/p>\r\n<h2>\u00bfSe conoce ya plenamente el potencial de estas tecnolog\u00edas?<\/h2>\r\n<p>En absoluto, a\u00fan es muy pronto para aplicar la IA a los retos de la atenci\u00f3n sanitaria. Hemos visto que la IA y los macrodatos tienen un gran impacto en el mundo de la informaci\u00f3n y en Internet, pero en los campos de la biolog\u00eda y la medicina, la era de los macrodatos a\u00fan est\u00e1 en sus inicios. Creo que veremos avances cada vez mayores en la pr\u00f3xima d\u00e9cada o dos, a medida que se recopilen y pongan a disposici\u00f3n m\u00e1s y m\u00e1s datos. Una de nuestras misiones en la Cl\u00ednica Jameel es formar a la pr\u00f3xima generaci\u00f3n de investigadores sanitarios para que sean multidisciplinares, de modo que tengan experiencia tanto en IA\/aprendizaje autom\u00e1tico como en biolog\u00eda y qu\u00edmica, lo que les permitir\u00e1 trabajar en la interfaz de la tecnolog\u00eda, la ciencia y la medicina para lograr avances importantes para los pacientes.<\/p>\r\n<h2>De cara al futuro, \u00bfc\u00f3mo cree que ser\u00e1 el futuro de la sanidad mundial a medio y largo plazo?<\/h2>\r\n<p>Creo que una de las pocas ventajas de la pandemia es la creciente concienciaci\u00f3n de los j\u00f3venes sobre la importancia de las enfermedades infecciosas como un tema serio que merece su atenci\u00f3n. Por lo tanto, creo que veremos m\u00e1s j\u00f3venes talentos entrar en el campo de las enfermedades infecciosas y la salud mundial, lo que sin duda har\u00e1 avanzar nuestros conocimientos y nuestras capacidades para detectar, tratar y prevenir las infecciones.<\/p>\r\n<p>De cara al futuro, no cabe duda de que asistiremos a cambios y avances espectaculares en la biomedicina. Veremos el creciente impacto de los macrodatos, las tecnolog\u00edas avanzadas, como la IA y la biolog\u00eda sint\u00e9tica, para avanzar en los esfuerzos que nos permiten diagnosticar mejor las enfermedades, tratarlas y prevenirlas en todo el mundo, de una manera econ\u00f3micamente eficiente y, esperamos, asequible para todos.<\/p>"],"_content":[""],"_ame_cpe_post_policy":["{\"accessProtection\":{\"active\":\"replace\"}}"],"_edit_last":["22"],"_wpml_media_duplicate":["1"],"_wpml_media_featured":["1"],"_yoast_wpseo_content_score":["90"],"_yoast_wpseo_estimated-reading-time-minutes":["1"]},"_links":{"self":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/wp-json\/wp\/v2\/perspectives\/14864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/wp-json\/wp\/v2\/perspectives"}],"about":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/wp-json\/wp\/v2\/types\/perspectives"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/wp-json\/wp\/v2\/media\/14852"}],"wp:attachment":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/wp-json\/wp\/v2\/media?parent=14864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}